Herszényi László M.D., Ph.D. – Associate Professor

Number of Publications:
Papers: 342
Specialized textbooks: 31
Scientific cumulative impact factor: 150; Citation index: 1068

Most important articles in English language

Herszényi L, Plebani M, Carraro P, De Paoli M, Di Mario F, Kusstatscher S, Rugge M, Cardin R, Naccarato R, Farinati F. Impaired fibrinolysis and protease activation in gastric and duodenal mucosa of patients with active duodenal ulcer.
Am J Gastroenterol 1997; 92: 843-847.

Herszényi L, Plebani M, Carraro P, De Paoli M, Roveroni R, Cardin R, Tulassay Z, Naccarato R, Farinati F. The role of cysteine and serine proteases in colorectal cancer.
Cancer 1999; 86: 1135-1142.     

Herszényi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin r, Foschia F, Tulassay Z, Naccarato R, Farinati F.  Proteases in gastrointestinal neoplastic diseases.
Clinica Chimica Acta 2000; 291: 171-187.     

Herszényi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, Tulassay Z. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis.
World J Gastroenterol 2007; 13 (5): 676-682.   

Herszényi L, Miheller P, Tulassay Z. Carcinogenesis in inflammatory bowel disease.  
Dig Dis 2007; 25: 267-269.                                

Herszényi L, Farinati F, Cardin R, István G, Molnár DL, Hritz I, De Paoli M, Plebani M, Tulassay Z. The tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
BMC Cancer 2008; 8: 194. /DOI10.1186/1471-2407-8-194/.          

Herszényi L, István G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F.  Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008; 17 (5): 438-445.     

Herszényi L, Farinati F, Miheller P, Tulassay Z. Chemoprevention of colorectal cancer: feasibility in the every day practice?  Eur J Cancer Prev 2008; 17: 502-514.

Herszényi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, Berczi L, Molnár B, Tulassay Z. Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.
Pathol Oncol Res 2008; 14 (1): 31-37.     

Pregun I, Hritz I, Tulassay Z, Herszényi L. Peptic stricture: medical treatment.
Dig Dis 2009 27: 31-37. DOI:10.1159/00210101.

Pregun I, Bakucz T, Banai J, Molnár L, Pavlik G, Altorjay I, Orosz P, Csernay L, Tulassay Z,
Herszényi L. Gastroesophageal reflux disease: Work-related disease?
Dig Dis 2009; 27: 38-44. DOI 10.1159/000210102.

Herszényi L, Pregun I, Tulassay Z. Diagnosis and recognition of early esophageal neoplasia.
Dig Dis 2009; 27: 24-30. DOI 10.1159/000210100.

Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258.

Herszényi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci 2012; 13: 13240-13263.

Herszényi L, Tulassay Z. The role of autoantibodies in inflammatory bowel disease. Dig Dis 2012; 3: 201-207.

Wittmann T, Stockbrugger R, Herszényi L. New European initiatives in colorectal cancer screening: Budapest Declaration. Dig Dis 2012; 30: 320-322.

Müllner K, MIheller P, Herszényi L, Tulassay Z. Probiotics in the management of Crohn's disease and ulcerative colitis. Curr Pharm Des 2014; 20: 4556-4560.

Mihály E, Székely H, Herszényi L, Wikonkál N, Tulassay Z. Letter: Dermatological complications with therapy for inflammatory bowel disease. APT 2014; 39: 232-233.

Herszényi L, Barabás L, Hritz I, István G, Tulassay Z. Impact of proteolytic enzymes in colorectal cancer development and prgoression. World J Gastroenterol 2014; 20: 13246-13257.

Herszényi L, Barabás L, Tulassay Z. Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. Dig Dis 2014; DOI:10.1159/000368447 (Epub ahead of print)